FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4284705771> ?p ?o ?g. }

• W4284705771 abstract "Cancer patients (CPs) have been identified as particularly vulnerable to SARS-CoV-2 infection, and therefore are a priority group for receiving COVID-19 vaccination. From the patients with advanced solid tumors, about 20% respond very efficiently to immunotherapy with anti-PD1/PD-L1 antibodies and achieve long lasting cancer responses. It is unclear whether an efficient cancer-specific immune response may also correlate with an efficient response upon COVID-19 vaccination. Here, we explored the antiviral immune response to the mRNA-based COVID-19 vaccine BNT162b2 in a group of 11 long-lasting cancer immunotherapy responders. We analysed the development of SARS-CoV-2-specific IgG serum antibodies, virus neutralizing capacities and T cell responses. Control groups included patients treated with adjuvant cancer immunotherapy (IMT, cohort B), CPs not treated with immunotherapy (no-IMT, cohort C) and healthy controls (cohort A). The median ELISA IgG titers significantly increased after the prime-boost COVID vaccine regimen in all cohorts (Cohort A: pre-vaccine = 900 (100-2700), 3 weeks (w) post-boost = 24300 (2700-72900); Cohort B: pre-vaccine = 300 (100-2700), 3 w post-boost = 8100 (300-72900); Cohort C: pre-vaccine = 500 (100-2700), 3 w post-boost = 24300 (300-72900)). However, at the 3 w post-prime time-point, only the healthy control group showed a statistically significant increase in antibody levels (Cohort A = 8100 (900-8100); Cohort B = 900 (300-8100); Cohort C = 900 (300-8100)) (P < 0.05). Strikingly, while all healthy controls generated high-level antibody responses after the complete prime-boost regimen (Cohort A = 15/15 (100%), not all CPs behaved alike [Cohort B= 12/14 (84'6%); Cohort C= 5/6 (83%)]. Their responses, including those of the long-lasting immunotherapy responders, were more variable (Cohort A: 3 w post-boost (median nAb titers = 95.32 (84.09-96.93), median Spike-specific IFN-γ response = 64 (24-150); Cohort B: 3 w post-boost (median nAb titers = 85.62 (8.22-97.19), median Spike-specific IFN-γ response (28 (1-372); Cohort C: 3 w post-boost (median nAb titers = 95.87 (11.8-97.3), median Spike-specific IFN-γ response = 67 (20-84)). Two long-lasting cancer responders did not respond properly to the prime-boost vaccination and did not generate S-specific IgGs, neutralizing antibodies or virus-specific T cells, although their cancer immune control persisted for years. Thus, although mRNA-based vaccines can induce both antibody and T cell responses in CPs, the immune response to COVID vaccination is independent of the capacity to develop an efficient anti-cancer immune response to anti PD-1/PD-L1 antibodies." @default.
• W4284705771 created "2022-07-08" @default.
• W4284705771 creator A5008577694 @default.
• W4284705771 creator A5014576413 @default.
• W4284705771 creator A5025543199 @default.
• W4284705771 creator A5029000068 @default.
• W4284705771 creator A5029331828 @default.
• W4284705771 creator A5029705489 @default.
• W4284705771 creator A5029783929 @default.
• W4284705771 creator A5036423133 @default.
• W4284705771 creator A5037744581 @default.
• W4284705771 creator A5044887899 @default.
• W4284705771 creator A5044979194 @default.
• W4284705771 creator A5047509232 @default.
• W4284705771 creator A5056891866 @default.
• W4284705771 creator A5059394059 @default.
• W4284705771 creator A5067203879 @default.
• W4284705771 creator A5072143967 @default.
• W4284705771 creator A5083185251 @default.
• W4284705771 date "2022-07-05" @default.
• W4284705771 modified "2023-10-06" @default.
• W4284705771 title "Brief Research Report: Anti-SARS-CoV-2 Immunity in Long Lasting Responders to Cancer Immunotherapy Through mRNA-Based COVID-19 Vaccination" @default.
• W4284705771 cites W3012925204 @default.
• W4284705771 cites W3016602372 @default.
• W4284705771 cites W3111255098 @default.
• W4284705771 cites W3121604662 @default.
• W4284705771 cites W3154805493 @default.
• W4284705771 cites W3155433545 @default.
• W4284705771 cites W3156866359 @default.
• W4284705771 cites W3157453497 @default.
• W4284705771 cites W3162395942 @default.
• W4284705771 cites W3162602895 @default.
• W4284705771 cites W3164768289 @default.
• W4284705771 cites W3166451371 @default.
• W4284705771 cites W3172958999 @default.
• W4284705771 cites W3182782630 @default.
• W4284705771 cites W3194227053 @default.
• W4284705771 cites W3197493891 @default.
• W4284705771 cites W3197610109 @default.
• W4284705771 cites W3198215920 @default.
• W4284705771 cites W3200240682 @default.
• W4284705771 cites W3200998454 @default.
• W4284705771 cites W3201233035 @default.
• W4284705771 cites W3202007017 @default.
• W4284705771 cites W3202209604 @default.
• W4284705771 cites W3210429879 @default.
• W4284705771 cites W4200022836 @default.
• W4284705771 cites W4200172406 @default.
• W4284705771 cites W4200581265 @default.
• W4284705771 cites W4205483821 @default.
• W4284705771 cites W4206987853 @default.
• W4284705771 cites W4226037559 @default.
• W4284705771 cites W4226258201 @default.
• W4284705771 doi "https://doi.org/10.3389/fimmu.2022.908108" @default.
• W4284705771 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35911701" @default.
• W4284705771 hasPublicationYear "2022" @default.
• W4284705771 type Work @default.
• W4284705771 citedByCount "3" @default.
• W4284705771 countsByYear W42847057712022 @default.
• W4284705771 countsByYear W42847057712023 @default.
• W4284705771 crossrefType "journal-article" @default.
• W4284705771 hasAuthorship W4284705771A5008577694 @default.
• W4284705771 hasAuthorship W4284705771A5014576413 @default.
• W4284705771 hasAuthorship W4284705771A5025543199 @default.
• W4284705771 hasAuthorship W4284705771A5029000068 @default.
• W4284705771 hasAuthorship W4284705771A5029331828 @default.
• W4284705771 hasAuthorship W4284705771A5029705489 @default.
• W4284705771 hasAuthorship W4284705771A5029783929 @default.
• W4284705771 hasAuthorship W4284705771A5036423133 @default.
• W4284705771 hasAuthorship W4284705771A5037744581 @default.
• W4284705771 hasAuthorship W4284705771A5044887899 @default.
• W4284705771 hasAuthorship W4284705771A5044979194 @default.
• W4284705771 hasAuthorship W4284705771A5047509232 @default.
• W4284705771 hasAuthorship W4284705771A5056891866 @default.
• W4284705771 hasAuthorship W4284705771A5059394059 @default.
• W4284705771 hasAuthorship W4284705771A5067203879 @default.
• W4284705771 hasAuthorship W4284705771A5072143967 @default.
• W4284705771 hasAuthorship W4284705771A5083185251 @default.
• W4284705771 hasBestOaLocation W42847057711 @default.
• W4284705771 hasConcept C121608353 @default.
• W4284705771 hasConcept C126322002 @default.
• W4284705771 hasConcept C143998085 @default.
• W4284705771 hasConcept C159654299 @default.
• W4284705771 hasConcept C201903717 @default.
• W4284705771 hasConcept C203014093 @default.
• W4284705771 hasConcept C22070199 @default.
• W4284705771 hasConcept C2777701055 @default.
• W4284705771 hasConcept C2777863537 @default.
• W4284705771 hasConcept C2780674031 @default.
• W4284705771 hasConcept C2781413609 @default.
• W4284705771 hasConcept C32611913 @default.
• W4284705771 hasConcept C71924100 @default.
• W4284705771 hasConcept C72563966 @default.
• W4284705771 hasConcept C8891405 @default.
• W4284705771 hasConceptScore W4284705771C121608353 @default.
• W4284705771 hasConceptScore W4284705771C126322002 @default.
• W4284705771 hasConceptScore W4284705771C143998085 @default.
• W4284705771 hasConceptScore W4284705771C159654299 @default.
• W4284705771 hasConceptScore W4284705771C201903717 @default.
• W4284705771 hasConceptScore W4284705771C203014093 @default.

• next